# Risk: __Expectations for vaccine__ (PBN__Risk_430)

## Property: has_RiskSubject

* [general population](../Stakeholder/PBN__Stakeholder_9)
* [public health officials](../Stakeholder/PBN__Stakeholder_310)

## Property: has_RiskISO_Impact

* [Governance, empowerment and engagement](../RiskISO/PBN__RiskISO_Purpose_6)

## Property: has_RiskSource

* [wu_current_2021](../Article/PBN__Article_118)

## Property: has_RiskName

Limited ability to prevent and control the spread of SARS-CoV-2 without effective vaccines.

## Property: has_RiskHealth

* [physical](../RiskHealth/PBN__RiskHealth_0)

## Property: has_RiskGBN

* [No](../RiskGBN/PBN__RiskGBN_0)

## Property: has_RiskTechnology

* [development of various vaccine strategies](../Technology/PBN__Technology_1960)
* [clinical trials](../Technology/PBN__Technology_1961)

## Property: has_RiskOwner

* [scientists](../Stakeholder/PBN__Stakeholder_46)
* [researchers](../Stakeholder/PBN__Stakeholder_2)
* [pharmaceutical companies](../Stakeholder/PBN__Stakeholder_124)

## Property: has_RiskType

* [technological](../RiskType/PBN__RiskType_5)

## Property: has_RiskDescription

The development of effective vaccines against SARS-CoV-2 is a critical measure for long-term protection.

## Property: has_RiskISO_Purpose

* [Resilience](../RiskISO/PBN__RiskISO_Impact_2)

## Property: has_RiskMitigation

* [Vaccine development](../RiskMitigation/PBN__RiskMitigation_598)
* [Continue research and development of vaccines against SARS-CoV-2.](../RiskMitigation/PBN__RiskMitigation_3065)

